|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02607 SH PHARMA
Nominal 
10.660 -0.120 (-1.113%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 275,250,935 | 5.746% | 260,295,089 | 231,981,300 | 215,824,259 | 191,909,156 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (636,682) | 45.859% | (436,505) | (425,194) | (345,767) | (742,161) | |
| Profit / (Loss) on Disposal | 187,968 | 103.263% | 92,475 | 1,438,918 | 58,289 | 52,149 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 521,909 | 303.552% | 129,329 | 526,743 | 789,596 | 1,009,547 | |
| Profit / (Loss) before Taxation | 8,020,007 | 13.690% | 7,054,297 | 8,808,353 | 8,143,815 | 7,175,483 | |
| Taxation | (2,149,995) | 13.893% | (1,887,726) | (1,816,339) | (1,869,245) | (1,570,219) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,317,483) | -5.798% | (1,398,571) | (1,374,863) | (1,181,102) | (1,109,047) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 4,552,528 | 20.821% | 3,768,000 | 5,617,152 | 5,093,467 | 4,496,217 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,480,912 | -0.326% | 1,485,758 | 1,313,192 | 1,245,369 | 1,239,584 |
| Depreciation & Amortisation | 2,609,899 | 9.685% | 2,379,459 | 2,417,627 | 2,326,697 | 2,298,453 |
| Directors' Emoluments | 6,708 | -63.676% | 18,467 | 20,595 | 19,753 | 18,111 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 123.000 | 20.588% | 102.000 | 161.000 | 179.000 | 158.000 |
| DPS (cts) | 37.000 | -- | 41.000 | 61.000 | 42.000 | 48.000 |
| Dividend Payout Ratio (%) | 30.081% | -- | 40.196% | 37.888% | 23.464% | 30.380% |
| Cash flow per share ($) | 1.573 | -- | 1.413 | 1.362 | 1.781 | 2.408 |
| NBV per share ($) | 19.330 | -- | 18.504 | 18.137 | 17.367 | 15.958 |
| Remarks: | Real time quote last updated: 28/04/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 4,552,528 |
| %Change | 20.821% |
| EPS / (LPS) | RMB 1.230 |
| NBV Per Share (¥) | RMB 19.330 |